SLXN

$1.56

Market ClosedAs of Mar 17, 8:00 PM UTC

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Recent News

TipRanks
May 30, 2025

Silexion Therapeutics announces preclinical results on SIL204

Silexion Therapeutics (SLXN) announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi therapeutic candidate, SIL204, against human pancreatic, colorectal and lung, NSCLC, cancer cell lines. These results significantly expand SIL204’s therapeutic potential beyond pancreatic cancer, allowing it to potentially address major KRAS-driven cancers with substantial unmet medical needs. Following the Company’s recent announcement of completion of preclinical studies, a

BEARISH
Negative press. News cycle fixated on risk factors or misses.